Biogenera

Biogenera is a private, pre-revenue biotech firm pioneering a novel class of DNA-based therapeutics using its proprietary Peptide Nucleic Acid (PNA) platform, MyGenera™. Its lead candidate, BGA002, targets the MYCN oncogene for pediatric cancers and has received Orphan Drug Designations, positioning it for clinical development. The company maintains a diversified preclinical pipeline targeting key oncology drivers like MYC and BCL2, as well as undisclosed metabolic and dermatological diseases, leveraging academic and industry partnerships to advance its programs.

Proprietary MyGenera™ platform for developing anti-gene Peptide Nucleic Acid (Ag-PNA) oligonucleotides. These synthetic molecules bind directly to specific DNA sequences to silence disease-causing genes at the transcriptional level.

Biogenera competes in the oligonucleotide therapeutics space, facing competition from companies using siRNA, antisense, and other gene silencing/modification technologies. Direct competitors include firms developing therapies for MYCN, MYC, and BCL2-driven cancers. Its differentiation lies in the direct DNA-targeting Ag-PNA approach, but it must prove advantages over established RNA-targeting modalities.